Aurobindo Pharma Limited (NSE:AUROPHARMA)
1,111.70
+12.30 (1.12%)
Oct 29, 2025, 3:30 PM IST
Aurobindo Pharma Revenue
Aurobindo Pharma had revenue of 78.68B INR in the quarter ending June 30, 2025, with 3.98% growth. This brings the company's revenue in the last twelve months to 320.25B, up 7.76% year-over-year. In the fiscal year ending March 31, 2025, Aurobindo Pharma had annual revenue of 317.24B with 9.39% growth.
Revenue (ttm)
320.25B
Revenue Growth
+7.76%
P/S Ratio
1.99
Revenue / Employee
11.56M
Employees
27,707
Market Cap
638.53B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 317.24B | 27.22B | 9.39% |
| Mar 31, 2024 | 290.02B | 41.46B | 16.68% |
| Mar 31, 2023 | 248.55B | 14.00B | 5.97% |
| Mar 31, 2022 | 234.55B | -13.19B | -5.32% |
| Mar 31, 2021 | 247.75B | 16.76B | 7.26% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 537.77B |
| Cipla | 274.80B |
| Zydus Lifesciences | 236.08B |
| Apollo Hospitals Enterprise | 225.51B |
| Biocon | 157.71B |
| Glenmark Pharmaceuticals | 134.56B |
| Alkem Laboratories | 133.04B |
| Mankind Pharma | 129.10B |
Aurobindo Pharma News
- 6 days ago - Aurobindo Pharma expands global footprint, incorporates new subsidiary in Chile to strengthen Latin American presence - Business Upturn
- 4 weeks ago - Why are Aurobindo Pharma shares falling over 2% today? Explained - Business Upturn
- 4 weeks ago - Gland Pharma down 4%, Sun Pharma slips 2.6%, Dr Reddy’s down 2%, Zydus nearly 3%, Aurobindo down 2% as Trump’s 100% pharma tariff jolts sector - Business Upturn
- 4 weeks ago - Indian pharma stocks in focus as Trump announces 100% tariff on branded drugs - Business Upturn
- 5 weeks ago - Aurobindo Pharma reports fire incident at its Andhra Pradesh unit - Business Upturn
- 5 weeks ago - Aurobindo Pharma’s CuraTeQ Biologics successfully completes Phase 3 study for denosumab biosimilar - Business Upturn
- 5 weeks ago - Top stocks to watch today, September 18: TVS Motor, Biocon, Aurobindo Pharma, Bandhan Bank, Federal Bank and more - Business Upturn
- 6 weeks ago - Why are Aurobindo Pharma shares up 5% today? Know More - Business Upturn